Rapt Therapeutics Announced That The FDA Has Verbally Notified Of A Clinical Hold Placed On The Company's Phase 2B Trial Of Zelnecirnon (RPT193) In Atopic Dermatitis And Its Phase 2A Trial In Asthma
Portfolio Pulse from Benzinga Newsdesk
Rapt Therapeutics has been informed by the FDA of a clinical hold on its Phase 2B trial of Zelnecirnon in atopic dermatitis and its Phase 2A trial in asthma due to a serious adverse event of liver failure in one patient. Dosing and enrollment have been halted in both trials. The hold does not affect RAPT's oncology trial of tivumecirnon.
February 20, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rapt Therapeutics faces a clinical hold on its Zelnecirnon trials for atopic dermatitis and asthma, following a serious adverse event. This halt could impact the company's development timeline and investor confidence.
The clinical hold directly impacts Rapt Therapeutics' ongoing trials for Zelnecirnon, potentially delaying the drug's development and affecting the company's valuation. The serious nature of the adverse event (liver failure) could lead to increased scrutiny from regulators and investors, negatively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100